References
- Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363 (8):711–1290. doi:https://doi.org/10.1056/NEJMoa1003466
- Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532. doi:https://doi.org/10.1056/NEJMoa1503093
- Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330. doi:https://doi.org/10.1056/NEJMoa1412082
- Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:https://doi.org/10.1056/NEJMoa1507643
- Fuchs CS, Doi T, Jang RW-J, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges J-P, et al. KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. JCO. 2017;35(15_suppl):4003. doi:https://doi.org/10.1200/JCO.2017.35.15_suppl.4003
- Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:https://doi.org/10.1016/S1470-2045(18)30351-6
- Hsu C, Lee S-H, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study. J Clin Oncol. 2017;35(36):4050–4056. doi:https://doi.org/10.1200/JCO.2017.73.3675
- Schellens JHM, Marabelle A, Zeigenfuss S, Ding J, Pruitt SK, Chung HC. Pembrolizumab for previously treated advanced cervical squamous cell cancer: preliminary results from the phase 2 KEYNOTE-158 study. JCO. 2017;35(15_suppl):5514–5514. doi:https://doi.org/10.1200/JCO.2017.35.15_suppl.5514
- Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, KEYNOTE-001 Investigators, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028. doi:https://doi.org/10.1056/NEJMoa1501824
- Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:https://doi.org/10.1056/NEJMoa1504627
- Bai R, Lv Z, Xu D, Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2020;8(34). doi:https://doi.org/10.1186/s40364-020-00209-0
- Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi:https://doi.org/10.1016/S0140-6736(15)01281-7
- Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–287. doi:https://doi.org/10.1038/nrc.2016.36
- Hellmann MD, Ciuleanu T-E, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104. doi:https://doi.org/10.1056/NEJMoa1801946
- Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501. doi:https://doi.org/10.1056/NEJMc1713444
- Peters S, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn M-J, et al. Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab +/- tremelimumab vs chemotherapy. Cancer Res. 2019;79(13 Supplement) CT074. doi: https://doi.org/10.1158/1538-7445.AM2019-CT074.
- Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128. doi:https://doi.org/10.1126/science.aaa1348
- Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. doi:https://doi.org/10.1056/NEJMoa1500596
- Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:https://doi.org/10.1126/science.aan6733
- Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J, Xin Y, Wang Y, Yang C, Cheng Y, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal. 2019;33(8):e22964. doi:https://doi.org/10.1002/jcla.22964
- Rossi S, Toschi L, Finocchiaro G, Santoro A. Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer. Immunotherapy. 2020;12(10):715–724. doi:https://doi.org/10.2217/imt-2019-0154
- Jin J, Yang L, Liu D, Li W. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis. Bmj Open. 2020;10(6):e035031. doi:https://doi.org/10.1136/bmjopen-2019-035031
- Rochet NM, Kottschade LA, Grotz TE, Porrata LF, Markovic SN. The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma. Am J Clin Oncol-Cancer Clin Trials. 2015;38(3):252–258. doi:https://doi.org/10.1097/COC.0b013e31829b5605
- Cassidy MR, Wolchok RE, Zheng J, Panageas KS, Wolchok JD, Coit D, Postow MA, Ariyan C. Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment. Ebiomedicine. 2017;18:56–61. doi:https://doi.org/10.1016/j.ebiom.2017.03.029
- Lalani A-KA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, et al. Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018;6(1):5. doi:https://doi.org/10.1186/s40425-018-0315-0
- Matsuki T, Okamoto I, Fushimi C, Sawabe M, Kawakita D, Sato H, Tsukahara K, Kondo T, Okada T, Tada Y, et al. Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients. Cancer Med. 2020;9(14):5015–5024. doi:https://doi.org/10.1002/cam4.3124
- Dharmapuri S, Özbek U, Lin J‐Y, Sung M, Schwartz M, Branch AD, Ang C. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy. Cancer Med. 2020;9 (14):4962–4970. doi:https://doi.org/10.1002/cam4.3135
- Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181. doi:https://doi.org/10.1016/j.lungcan.2017.07.024
- Svaton M, Zemanova M, Skrickova J, Jakubikova L, Kolek V, Kultan J, Koubkova L, Bejckova A, Salajka F, Hrnciarik M, et al. Chronic inflammation as a potential predictive factor of nivolumab therapy in non-small cell lung cancer. Anticancer Res. 2018;38 (12):6771–6782. doi:https://doi.org/10.21873/anticanres.13048
- Lenci E, Cantini L, Pecci F, Cognigni V, Agostinelli V, Mentrasti G, Lupi A, Ranallo N, Paoloni F, Rinaldi S, et al. The Gustave roussy immune (GRIm)-score variation is an early-on-treatment biomarker of outcome in advanced non-small cell lung cancer (NSCLC) patients treated with first-line pembrolizumab. JCM. 2021 Mar 2;10(5):1005. doi:https://doi.org/10.3390/jcm10051005
- Banna GL, Cortellini A, Cortinovis DL, Tiseo M, Aerts JGJV, Barbieri F, Giusti R, Bria E, Grossi F, Pizzutilo P, et al. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer. ESMO Open. 2021;6(2):100078. doi:https://doi.org/10.1016/j.esmoop.2021.100078
- Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, Berruti A, Falcone A, Aieta M, Gelibter A, et al. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): A large retrospective multicenter study. Adv Ther. 2020;37(3):1145–1155. doi:https://doi.org/10.1007/s12325-020-01229-w
- Muliawati Y, Haroen H, Rotty LWA. Cancer anorexia - cachexia syndrome. Acta Med Indones. 2012;44(2):154–162.
- McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223–226.
- Inoue T, Tamiya M, Tamiya A, Nakahama K, Taniguchi Y, Shiroyama T, Isa S-i, Nishino K, Kumagai T, Kunimasa K, et al. Analysis of early death in japanese patients with advanced non-small-cell lung cancer treated with nivolumab. Clinical Lung Cancer. 2018;19(2):E171–E176. doi:https://doi.org/10.1016/j.cllc.2017.09.002
- Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Mimae T, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, et al. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. Int J Clin Oncol. 2020;25(1):74–81. doi:https://doi.org/10.1007/s10147-019-01539-2
- Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J. 2010;9:69. doi:https://doi.org/10.1186/1475-2891-9-69
- Gabay C, Kushner I. Mechanisms of disease: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340 (6):448–454. doi:https://doi.org/10.1056/NEJM199902113400607
- Gundog M, Basaran H. Pretreatment low prognostic nutritional index and low albumin-globulin ratio are predictive for overall survival in nasopharyngeal cancer. Eur Arch Otorhinolaryngol. 2019;276(11):3221–3230. doi:https://doi.org/10.1007/s00405-019-05595-2
- Chen W-Z, Yu S-T, Xie R, Lv Y-X, Xu D-B, Yu J-C. Preoperative albumin/globulin ratio has predictive value for patients with laryngeal squamous cell carcinoma. Oncotarget. 2017;8(29):48240–48247. doi:https://doi.org/10.18632/oncotarget.18443
- Oki S, Toiyama Y, Okugawa Y, Shimura T, Okigami M, Yasuda H, Fujikawa H, Okita Y, Yoshiyama S, Hiro J, et al. Clinical burden of preoperative albumin-globulin ratio in esophageal cancer patients. Am J Surg. 2017;214(5):891–898. doi:https://doi.org/10.1016/j.amjsurg.2017.04.007
- Xiao S, Feng F, Liu N, Liu Z, Guo Y, Lian X, Zhang H. Preoperative albumin level is superior to albumin-globulin ratio as a predicting indicator in gastric cancer patients who underwent curative resection. Cancer Manag Res. 2019;11:9931–9938. doi:https://doi.org/10.2147/CMAR.S230741
- Deng Y, Pang Q, Miao R-C, Chen W, Zhou Y-Y, Bi J-B, Liu S-S, Zhang J-Y, Qu K, Liu C, et al. Prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma. OTT. 2016;9:5317–5328. doi:https://doi.org/10.2147/OTT.S109736
- Liu J, Dai Y, Zhou F, Long Z, Li Y, et al. The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. Urologic Oncology-Seminars and Original Investigations. 2016;34(11):484.e1–484.e8. doi:https://doi.org/10.1016/j.urolonc.2016.05.024
- Wang Y, Li S, Hu X, Wang Y, Wu Y, Li P, Che G. The prognostic value of serum albumin-globulin ratio in early-stage non-small cell lung cancer: a retrospective study. CMAR. 2019;11:3545–3554. doi:https://doi.org/10.2147/CMAR.S191288
- Hollande C, Boussier J, Ziai J, Nozawa T, Bondet V, Phung W, Lu B, Duffy D, Paradis V, Mallet V, et al. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nat Immunol. 2019;20(3):257–264. doi:https://doi.org/10.1038/s41590-019-0321-5
- Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AMM, Routier E, Robert C, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013;24(6):1697–703. doi:https://doi.org/10.1093/annonc/mdt027
- McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, DeVries T, Sheikh NA, Dreicer R, et al. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol Res. 2014;2(10):988–999. doi:https://doi.org/10.1158/2326-6066.CIR-14-0073
- Tanizaki J, Haratani K, Hayashi H, Chiba Y, Nakamura Y, Yonesaka K, Kudo K, Kaneda H, Hasegawa Y, Tanaka K, et al. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol. 2018;13(1):97–105. doi:https://doi.org/10.1016/j.jtho.2017.10.030
- Mestas J, Hughes CCW. Of mice and not men: Differences between mouse and human immunology. J Immunol. 2004;172(5):2731–2738. doi:https://doi.org/10.4049/jimmunol.172.5.2731
- Granot Z. Neutrophils as a therapeutic target in cancer. Front Immunol. 2019;10:1710. doi:https://doi.org/10.3389/fimmu.2019.01710
- Oya Y, Yoshida T, Kuroda H, Mikubo M, Kondo C, Shimizu J, Horio Y, Sakao Y, Hida T, Yatabe Y, et al. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget. 2017;8(61):103117–103128. doi:https://doi.org/10.18632/oncotarget.21602
- Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 2017;5(5):417–424. doi:https://doi.org/10.1158/2326-6066.CIR-16-0325